

## CLAIMS

1.- 11 (deleted)

12. (currently amended) Method of treatment of an individual suffering from a disease selected from the group consisting of insulin resistance, hyperpigmentation and/or inflammatory processes in the skin, fungal diseases, overweight and obesity, and microbacterial infections, comprising administering to said individual an effective amount of a composition comprising a derivative of deoxynojirimycin, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier Use according to claim 10, wherein said derivative comprises a large hydrophobic moiety is derived from a compound selected from the group consisting of adamantanemethanol, cholesterol, .beta.-cholesterol, adamantanol and 9-hydroxyphenanthrene.

13. (currently amended) Use the Method of treatment of claim 12 according to claim 9, wherein said derivative further comprises an apolar side chain is derived from a polycyclic alcohol containing three or more rings each sharing two or more carbon atoms with another ring and is capable of inserting in lipid bilayers, and wherein the spacer comprises comprising an alkoxy polyalkene or polyalkene chain of from 3 to 8 carbon atoms.

14.(deleted).

15. (currently amended) Method of treatment of an individual suffering from insulin resistance, comprising administering to said individual an effective amount of a medicament composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin a deoxynojirimycin derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which deoxynojirimycin derivative or salt is an inhibitor of glucosyleeramide synthase.

16. (currently amended) Method of treatment of an individual suffering from a disease selected from the group consisting of hyperpigmentation and/or inflammatory processes in the skin, fungal diseases, overweight and obesity, and microbacterial infections, comprising administering to said individual an effective amount of a medicament composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin a deoxynojirimycin derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

17. (new) Method of treatment of an individual suffering from insulin resistance, said method comprising administering to said individual suffering overweight or obesity an effective amount of a composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.